Renaissance Technologies LLC grew its position in MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 47.9% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 281,200 shares of the company's stock after buying an additional 91,100 shares during the period. Renaissance Technologies LLC owned approximately 0.27% of MaxCyte worth $1,170,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Prudential Financial Inc. bought a new stake in MaxCyte in the 4th quarter worth about $65,000. Catalyst Funds Management Pty Ltd bought a new stake in shares of MaxCyte in the fourth quarter worth $74,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of MaxCyte by 10.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 22,366 shares of the company's stock worth $93,000 after acquiring an additional 2,154 shares during the period. EntryPoint Capital LLC bought a new position in MaxCyte in the fourth quarter valued at about $185,000. Finally, SG Americas Securities LLC grew its stake in shares of MaxCyte by 25.9% during the 4th quarter. SG Americas Securities LLC now owns 47,805 shares of the company's stock valued at $199,000 after purchasing an additional 9,836 shares during the period. Institutional investors own 68.81% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities analysts have weighed in on the stock. Stifel Nicolaus dropped their price target on shares of MaxCyte from $11.00 to $9.00 and set a "buy" rating for the company in a research report on Wednesday, March 12th. BTIG Research set a $6.00 price target on shares of MaxCyte and gave the stock a "buy" rating in a research note on Wednesday, March 12th.
Get Our Latest Stock Analysis on MaxCyte
MaxCyte Stock Performance
MXCT stock traded down $0.10 during mid-day trading on Monday, reaching $2.72. 29,487 shares of the stock traded hands, compared to its average volume of 626,024. MaxCyte, Inc. has a one year low of $2.21 and a one year high of $5.26. The stock has a market capitalization of $289.17 million, a PE ratio of -8.00 and a beta of 1.39. The business has a 50-day moving average price of $2.92 and a two-hundred day moving average price of $3.66.
About MaxCyte
(
Free Report)
MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Featured Articles
Before you consider MaxCyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.
While MaxCyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
